Verastem (VSTM) Cost of Revenue (2018 - 2026)

Name: Verastem (VSTM) Cost of Revenue (2018 - 2026) | Business Quant
Creator: Business Quant

Verastem's quarterly Cost of Revenue came in at $2.8 million in Q1 2026, up 6.13% quarter-over-quarter from $2.6 million in Q4 2025.

Verastem has reported Cost of Revenue for 5 years, with the latest figure at $2.8 million in Q1 2026.

For the quarter ending Q1 2026, Cost of Revenue changed N/A year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $7.4 million (changed N/A YoY), and the FY2025 full-year result was $4.6 million, changed N/A from the prior year.
Cost of Revenue for Q1 2026 stood at $2.8 million, up from $2.6 million in the prior quarter.
The five-year high for Cost of Revenue was $2.8 million in Q1 2026, with the low at $318000.0 in Q2 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Quantum Biopharma	1,216,509.61 Bn	1,216,509.61 Bn	-	-
2	Alterity Therapeutics	764,224.41 Bn	764,224.38 Bn	-	-
3	Legend Biotech	2,716.00 Bn	2,715.71 Bn	242.10 Mn	64.20 Mn
4	Nanobiotix	2,248.83 Bn	2,248.77 Bn	-	-
5	Akari Therapeutics	1,951.18 Bn	1,951.17 Bn	-	-
6	Vertex Pharmaceuticals	113.69 Bn	106.44 Bn	2.59 Bn	392.80 Mn
7	Evaxion A	64.16 Bn	64.14 Bn	-	-
8	Regeneron Pharmaceuticals	63.94 Bn	55.18 Bn	3.31 Bn	296.00 Mn
9	Alnylam Pharmaceuticals	40.13 Bn	37.12 Bn	959.66 Mn	207.52 Mn
10	Verastem	425.60 Mn	243.93 Mn	15.90 Mn	2.77 Mn

Download Data 🔒